Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

May 14, 2025

- *New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment*
- *The company will celebrate on social media, sharing patient and provider stories that highlight the impact NeuroStar has as a safe, effective, and non-drug treatment for depression*

MALVERN, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, is proud to launch the first National TMS Therapy Awareness Day. The event will take place each year on May 14 during May's Mental Health Awareness Month. This day is dedicated to raising awareness of transcranial magnetic stimulation (TMS) as a proven, non-drug treatment option for individuals living with major depressive disorder (MDD), depression with anxiety, and OCD, especially those who have not found relief through antidepressants.

"National TMS Awareness Day is about giving hope to people who haven't found relief and being a driving force in the National Mental Health Awareness conversation," said Keith Sullivan, President and Chief Executive Officer of Neuronetics. "Far too many individuals feel stuck or discouraged after trying multiple antidepressants without receiving adequate relief from their symptoms. By launching this National Day, we want to raise awareness that non-medication approaches like NeuroStar TMS therapy exist—and they're helping real people reclaim their lives. Our goal is to make sure every patient, caregiver, and provider knows that effective, non-drug treatments are available and within reach."

Transcranial magnetic stimulation was first cleared by the FDA in 2008 for treatment-resistant depression in adults. Since then, it has become a widely adopted, evidence-backed modality for those who haven't responded to medication intervention. NeuroStar is the leading TMS therapy in the United States—and in 2024, NeuroStar also received FDA clearance for use in adolescents, expanding access to younger patients in need of non-drug treatment options. Over 300 million people have insurance plans that cover NeuroStar TMS therapy, including Medicare and Tricare.

"One of the reasons NeuroStar is the leading TMS therapy is the precision of our technology," said Geoffrey Grammer, MD, Chief Medical Officer of Neuronetics. "Our unique coil design is built to deliver focused magnetic pulses exactly where they're needed. Combined with our Contact Sensing feature, this ensures every session is both consistent and effective, helping patients get the most out of their treatment. We take pride in our scientific and engineering rigor, which continues to advance the field of TMS therapy and enhance the lives of our patients. On National TMS Therapy Awareness Day, we celebrate the real-world impact of NeuroStar TMS Therapy and the difference it makes."

Kristen Gingrich, a licensed clinical social worker, mother, and patient advocate, has documented her experience with NeuroStar TMS after struggling with depression since her teens—worsened by postpartum challenges. After trying talk therapy and multiple antidepressants without lasting relief, she turned to NeuroStar TMS and is now sharing her treatment journey during Mental Health Awareness Month. Kristen's story, which can be seen on both her account (@notyouraveragethrpst) and NeuroStar social media channels, helps shine a light about non-drug options and inspire others facing similar struggles to seek help.

In addition to founding this awareness day, NeuroStar TMS continues its legacy as the leading TMS device company by presenting data at the 2025 American Psychiatric Association Annual Meeting (May 17-21). The poster "The Profile of Symptom Change with Transcranial Magnetic Stimulation for Major Depressive Disorder" builds on prior research and evaluates TMS protocols and their treatment efficacy.

To learn more about TMS Awareness Day and NeuroStar TMS therapy, visit TMSAwareness.com.

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) CIII Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.[1] Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner

ICR Healthcare
443-213-0499
ir@neuronetics.com

Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

References:

1. World Health Organization, Depression Fact Sheet. Accessed April 29, 2024. https://www.who.int/news-room/fact-sheets/detail/depression.

[1] The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

Neuronetics

Source: Neuronetics